Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial

Chin Wong, Ajit Dash, Jill Fredrickson, Nicholas Lewin‐Koh, Shan Chen, Kenta Yoshida, Yanqiu Liu, Johnny Gutierrez, Rebecca Kunder – 21 August 2022

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein – 21 August 2022

Genetic predisposition to porto‐sinusoidal vascular disorder: A functional genomic‐based, multigenerational family study

Jingxuan Shan, André Megarbane, Aziz Chouchane, Deepak Karthik, Ramzi Temanni, Atilio Reyes Romero, Huiying Hua, Chun Pan, Xixi Chen, Murugan Subramanian, Chadi Saad, Hamdi Mbarek, Cybel Mehawej, Eliane Chouery, Sirin W. Abuaqel, Alexander Dömling, Sami Remadi, Cesar Yaghi, Pu Li, Lotfi Chouchane – 20 August 2022

Attacking the public health crisis of hepatocellular carcinoma at its roots

Hannah M. Lee, Steven D. Lidofsky, Tamar H. Taddei, Lisa J. Townshend‐Bulson – 20 August 2022 – As the third most common cause of cancer‐related death worldwide with significant mortality rates in the United States, hepatocellular carcinoma has strong association with cirrhosis and chronic hepatitis B virus (HBV) with a growing at‐risk population from the rise in chronic liver disease from alcohol use and nonalcoholic fatty liver disease.

Early experiences with developing techniques for pure laparoscopic explant hepatectomy in living donor liver transplantation

Jane Chungyoon Kim, Suk Kyun Hong, Kwang‐Woong Lee, Sola Lee, Sanggyun Suh, Su young Hong, Eui Soo Han, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh – 20 August 2022 – In recent years, laparoscopic techniques for liver resection or living donor hepatectomy have become common surgical methods. However, reports on laparoscopic surgeries for recipients are lacking. Our center has launched the minimally invasive living donor liver transplantation (LDLT) program in March 2020, which is led by two surgeons who are experienced in laparoscopic surgeries.

The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma

Romain Donne, Amaia Lujambio – 20 August 2022 – The liver is the sixth most common site of primary cancer in humans and the fourth leading cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for 90% of liver cancers. HCC is a prevalent disease with a progression that is modulated by the immune system. Half of the patients with HCC receive systemic therapies, traditionally sorafenib or lenvatinib, as a first‐line therapy.

Subscribe to